Literature DB >> 19878401

Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring.

Christian Rose1, Eva-Bettina Bröcker, Detlef Zillikens.   

Abstract

BACKGROUND: Dermatitis herpetiformis is a chronic severely pruritic dermatosis. It is a cutaneous manifestation of celiac disease. The aim of our study was to collect clinical, histological and immunopathological data on patients who were treated in the University Departments of Dermatology in Würzburg and Lübeck from 1996 to 2008. PATIENTS AND METHODS: We retrospectively analyzed 32 patients. Only patients with positive findings on direct immunofluorescence microscopy were included in this study.
RESULTS: All patients demonstrated skin lesions in the predilection areas of knees, elbows, gluteal region and scalp. The male to female ratio was 1.5 : 1 and the average age was 43 years. The interval between the first symptoms and diagnosis ranged from 6 weeks to 20 years. Direct immunofluorescence microscopy showed that granular IgA deposits were more often found continuously along the dermal-epidermal junction rather than focally in the tips of the dermal papillae. Results of small intestinal biopsies were available from 29 patients and confirmed the presence of celiac disease in all cases. None of the patients reported gastrointestinal symptoms. IgA antibodies against tissue transglutaminase and epidermal transglutaminase were found in 88% and 94% of patient sera, respectively.
CONCLUSIONS: The detection of IgA autoantibodies against epidermal transglutaminase is the most sensitive serological test in the diagnosis of dermatitis herpetiformis. Our observations confirm that patients with dermatitis herpetiformis usually do not demonstrate apparent gastrointestinal symptoms.

Entities:  

Mesh:

Year:  2009        PMID: 19878401     DOI: 10.1111/j.1610-0387.2009.07292.x

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  7 in total

1.  Remission in dermatitis herpetiformis: a cohort study.

Authors:  So Yeon Paek; Seth M Steinberg; Stephen I Katz
Journal:  Arch Dermatol       Date:  2010-11-15

2.  Association between levels of IgA antibodies to tissue transglutaminase and gliadin-related nonapeptides in dermatitis herpetiformis.

Authors:  Justyna Gornowicz-Porowska; Monika Bowszyc-Dmochowska; Agnieszka Seraszek-Jaros; Elżbieta Kaczmarek; Marian Dmochowski
Journal:  ScientificWorldJournal       Date:  2012-04-01

3.  Dermatitis herpetiformis: pathophysiology, clinical presentation, diagnosis and treatment.

Authors:  Marcos Vinícius Clarindo; Adriana Tomazzoni Possebon; Emylle Marlene Soligo; Hirofumi Uyeda; Roseli Terezinha Ruaro; Julio Cesar Empinotti
Journal:  An Bras Dermatol       Date:  2014 Nov-Dec       Impact factor: 1.896

Review 4.  Dermatitis Herpetiformis: An Update on Diagnosis and Management.

Authors:  Timo Reunala; Kaisa Hervonen; Teea Salmi
Journal:  Am J Clin Dermatol       Date:  2021-05       Impact factor: 7.403

Review 5.  Review: dermatitis herpetiformis.

Authors:  Fernanda Berti Rocha Mendes; Adaucto Hissa-Elian; Marilda Aparecida Milanez Morgado de Abreu; Virgínica Scaff Gonçalves
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

6.  Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease.

Authors:  Emiliano Antiga; Veronica Bonciolini; Simone Cazzaniga; Mauro Alaibac; Antonino Salvatore Calabrò; Carla Cardinali; Emanuele Cozzani; Angelo Valerio Marzano; Giuseppe Micali; Tarcisio Not; Pietro Quaglino; Camilla Vassallo; Luigi Naldi; Marzia Caproni
Journal:  Biomed Res Int       Date:  2019-12-29       Impact factor: 3.411

Review 7.  An updated overview of spectrum of gluten-related disorders: clinical and diagnostic aspects.

Authors:  Nazanin Taraghikhah; Sara Ashtari; Nastaran Asri; Bijan Shahbazkhani; David Al-Dulaimi; Mohammad Rostami-Nejad; Mostafa Rezaei-Tavirani; Mohammad Reza Razzaghi; Mohammad Reza Zali
Journal:  BMC Gastroenterol       Date:  2020-08-06       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.